M3D, Inc

About M3D, Inc

M3D, Inc sits in Other / Uncategorized, a segment Bracken sees as structurally important to the radiopharma value chain.

Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.

What we're seeing

• Reuters Health · 2026-05-20
  M3d Inc expands cyclotron capacity to meet Lu-177 demand
  The work builds on more than a decade of radiochemistry collaboration.
• Endpoints News · 2026-10-03
  M3d Inc announces Phase II readout for lead theranostic candidate
  The announcement comes amid tightening Mo-99 and Lu-177 supply.
• FierceBiotech · 2026-11-22
  M3d Inc appoints new Chief Medical Officer ahead of pivotal trial
  Coverage notes the company's growing footprint in the radioligand therapy space.
• BioPharma Reporter · 2026-08-01
  M3d Inc signs supply agreement to support late-stage trials
  Details remain limited but analysts read the move as a positioning play ahead of pivotal data.
• Imaging Wire · 2026-09-08
  M3d Inc closes Series C round to scale radiopharma manufacturing
  Details remain limited but analysts read the move as a positioning play ahead of pivotal data.

Mocked while we wire the Exa integration. Headlines are illustrative.

What we expect to see at the booth

Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.